HLB Life Science Co., Ltd. acquired remaining 48.3% stake in Shinwhaadvance.Co.Ltd from Growth Enterprise Venture Capital Fund 1, C Square Unicorn Private Investment Trust 1, C Square Unicorn Pre-IPO Private Investment Trust 3, E&Healthcare Investment Fund No.1, BFA Co.,Ltd. and DTNI-Soft Industry Promotion Fund, a fund managed by Dt& Investment Co.,Ltd.
April 21, 2019
Share
HLB Life Science Co., Ltd. (KOSDAQ:A067630) acquired remaining 48.3% stake in Shinwhaadvance.Co.Ltd from Growth Enterprise Venture Capital Fund 1, C Square Unicorn Private Investment Trust 1, C Square Unicorn Pre-IPO Private Investment Trust 3, E&Healthcare Investment Fund No.1, BFA Co.,Ltd. and DTNI-Soft Industry Promotion Fund, a fund managed by Dt& Investment Co.,Ltd., on April 22, 2019. HLB Life Science Co., Ltd. acquired 0.12 million shares. In a related transaction, HLB Life Science Co., Ltd. acquired 0.049 million new shares in Shinwhaadvance.Co.Ltd. HLB Life Science Co., Ltd. holds 0.3 million shares after acquiring existing and new shares. The total consideration for existing and news shares is KRW 17.6 billion. As of December 31, 2018, Shinwhaadvance.Co.Ltd reported total assets of KRW 42.2 billion and total capital of KRW 7.9 billion. For the year ended December 31, 2018, Shinwhaadvance.Co.Ltd reported sales of KRW 96.7 billion and net profit of KRW 135 million. The Board of Directors of HLB Life Science Co., Ltd. resolved the transaction on April 22, 2019.
HLB Life Science Co., Ltd. (KOSDAQ:A067630) completed the acquisition of remaining 48.3% stake in Shinwhaadvance.Co.Ltd from Growth Enterprise Venture Capital Fund 1, C Square Unicorn Private Investment Trust 1, C Square Unicorn Pre-IPO Private Investment Trust 3, E&Healthcare Investment Fund No.1, BFA Co.,Ltd. and DTNI-Soft Industry Promotion Fund, a fund managed by Dt& Investment Co.,Ltd., on April 22, 2019.
HLB Life Science Co., Ltd. is a Korea-based company mainly engaged in the sale of pharmaceuticals. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. It is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.
HLB Life Science Co., Ltd. acquired remaining 48.3% stake in Shinwhaadvance.Co.Ltd from Growth Enterprise Venture Capital Fund 1, C Square Unicorn Private Investment Trust 1, C Square Unicorn Pre-IPO Private Investment Trust 3, E&Healthcare Investment Fund No.1, BFA Co.,Ltd. and DTNI-Soft Industry Promotion Fund, a fund managed by Dt& Investment Co.,Ltd.
HLB LIFE SCIENCE CO., LTD. 
